Lamotrigine hydrate
Modify Date: 2024-01-03 20:59:58
Lamotrigine hydrate structure
|
Common Name | Lamotrigine hydrate | ||
|---|---|---|---|---|
| CAS Number | 375347-20-9 | Molecular Weight | 274.11 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C9H9Cl2N5O | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Lamotrigine hydrateLamotrigine hydrate is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine hydrate selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine hydrate can be used for the research of epilepsy, focal seizure, et al[1][2]. |
| Name | Lamotrigine hydrate |
|---|
| Description | Lamotrigine hydrate is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine hydrate selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine hydrate can be used for the research of epilepsy, focal seizure, et al[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Lamotrigine hydrate inhibits Veratrine evoked release of glutamate and aspartate with ED50 values of 21 μM for both amino acids, but Lamotrigine hydrate is less potent in the inhibition of GABA release (ED50=44 μM. At concentrations up to 300 μM, LTG has no effect on patassium-evoked amino acid[1]. Lamotrigine hydrate is some five times less potent in the inhibition of Veratrine-evoked [3H]acetylcholine release (ED50=100 μM) than in glutamate or aspartate release[1]. |
| In Vivo | Lamotrigine hydrate (IP, 30 min before pentylenetetrazol; 10 mg/kg, 15 mg/kg or 20 mg/kg) decreases the seizure intensity at the higher doses, it increases the latency to the first pentylenetetrazol-induced seizure in all studied doses compared with the controls[2]. |
| References |
| Molecular Formula | C9H9Cl2N5O |
|---|---|
| Molecular Weight | 274.11 |